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Strategy With Ezetimibe
and Atorvastatin on
Coronary Plaque
Regression After PCI
PRECISE-IVUSWe read with interest the recent publication in the
Journal by Tsujita et al. (1). Treatment with the
atorvastatin/ezetimibe combination showed greater
coronary plaque regression; statistical analysis was
performed according to previous intravascular
ultrasound (IVUS) studies. Scrutiny of Table 1 reveals
that there was an excess (12%) of current smokers in
the statin monotherapy group (p ¼ 0.056 using the
Fisher exact test). Smoking is a major risk factor for
premature coronary atherosclerosis and acute
coronary syndromes. Might the difference in current
smokers between the 2 groups have affected the
results and thus favored the group receiving
combination lipid-lowering therapy? That said, careful
review of studies using serial IVUS for assessment of
coronary atheroma progression/regression revealed
omission of consideration of current smoking as a key
factor of immediate relevance (2–4).
Thus, smoking is well established as a risk factor
for CAD, and stopping smoking is one of the principal
measures recommended in secondary prevention of
CAD; however, serial IVUS measures of coronary
atheroma in secondary prevention have not to dateconﬁrmed that smoking is associated with disease
progression.
The recent report of Bolorunduro et al. (5) using
virtual histology IVUS showed that cigarette
smoking is associated with a higher burden of
necrotic core in coronary lesions. Because necrotic
core burden has been consistently shown to predict
the presence of vulnerable plaque, these ﬁndings
could suggest that even if smoking is not associated
with coronary plaque progression, cigarette smoking
increases vulnerable plaque burden and thus the
potential for acute clinical coronary syndromes.
Clearly, further investigation of the impact of
current smoking on coronary plaque progression,
assessed by serial IVUS, is warranted.*Philippe Giral, MD
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PRECISE-IVUSWe read with great interest the letter by Dr. Giral and
colleagues commenting on our recent paper (1). First
